This 1-year, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of zonisamide, an antiepileptic drug, for weight reduction in 225 obese adults (mean BMI 37.6 kg/m²) without diabetes. Participants received daily doses of placebo, 200 mg zonisamide, or 400 mg zonisamide, alongside diet and lifestyle counseling. At 12 months,
